Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Avalo Therapeutics' Receivables - Net history runs 8 years deep, the most recent figure standing at $38000.0 for Q2 2023.

• Quarterly Receivables - Net fell 95.78% year-over-year to $38000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $38000.0 (down 95.78% YoY) and the FY2021 annual result came in at $1.1 million, down 51.31% from the prior year.
• Receivables - Net was $38000.0 for Q2 2023 at Avalo Therapeutics, down from $800000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $5.5 million in Q1 2019 and bottomed at $38000.0 in Q2 2023.
• A 5-year average of $1.9 million and a median of $1.6 million in 2020 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2019 — Receivables - Net jumped 3149.59% — and 2023, when it slumped 95.78%.
• Avalo Therapeutics' Receivables - Net stood at $1.0 million in 2019, then surged by 117.34% to $2.2 million in 2020, then sank by 51.31% to $1.1 million in 2021, then slipped by 24.53% to $800000.0 in 2022, then plunged by 95.25% to $38000.0 in 2023.
• Business Quant data shows AVTX's Receivables - Net at $38000.0 in Q2 2023, $800000.0 in Q3 2022, and $900000.0 in Q2 2022.